Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy

This trial studies how well increasing the dose of survivorship care planning improves care
and outcomes in prostate cancer survivors receiving radiation therapy and androgen
deprivation therapy. There is a need for coordinated care between the cancer care team with
the primary care team. This is especially important for prostate cancer survivors who need
routine cancer care follow-up with their radiation oncologist and also coordinated routine
follow-up with their primary care provider (PCP). This is important because androgen
deprivation therapy increases a patient's risk for developing diabetes, hypercholesterolemia,
and cardiovascular events. Increasing the dose of survivorship may improve care and outcomes
of cancer survivors than standard practices.

Intervention

Questionnaire Administration, Survivorship Care Plan (SCP), Treatment Plan

Condition

Cancer Survivor, Prostate Adenocarcinoma

Investigators

Ronald C Chen, John A. Ellerton, Gregory A. Masters, Robert M. Doline, Bryan A. Faller, Patrick D. Maguire, Thomas E. Lad, Ki Y. Chung, Sharad A. Ghamande, Matthew D. Cheney, Samantha A. Seaward, Pamala A. Pawloski, Timothy D. Moore, Jay W. Carlson, Shannon Offerman, Kathleen J. Yost, Leander Cannick, Ronald C. Chen, Anand Mahadevan, Pamela J. Vetter, Vamsi K. Vasireddy, Jeremy M. Kilburn, Stephen C. King, Neda Hashemi Sadraei, Robert J. Isaak, Robert D. Siegel, Sandip M. Prasad, Keith R. Unger

See list of participating sites